Jeffrey V. Poulton, EVP, Chief Financial Officer at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 1,423 shares at $252.50 ($362K) on 2025-02-14, disclosed to the SEC on 2025-02-18.
Open-market sale of $362k ALNY by EVP, Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $252.50 | 217 | $55K | 15.1% |
| 2 | $252.50 | 217 | $55K | 15.1% |
| 3 | $253.37 | 239 | $61K | 16.7% |
| 4 | $253.37 | 239 | $61K | 16.7% |
| 5 | $254.35 | 160 | $41K | 11.2% |
| 6 | $255.56 | 68 |
| $17K |
| 4.8% |
| 7 | $256.29 | 78 | $20K | 5.5% |
| 8 | $257.51 | 37 | $10K | 2.6% |
| 9 | $258.07 | 47 | $12K | 3.3% |
| 10 | $259.72 | 17 | $4K | 1.2% |
| 11 | $260.57 | 30 | $8K | 2.2% |
| 12 | $261.45 | 37 | $10K | 2.7% |
| 13 | $263.33 | 17 | $4K | 1.2% |
| 14 | $264.87 | 20 | $5K | 1.5% |
| Total | $254.46 avg | 1,423 | $362K | 100% |
| Filing → |
| ALNY | SELL | 2026-02-17 | $695K | — | Filing → |
| ALNY | SELL | 2026-01-14 | $1.0M | — | Filing → |
| ALNY | SELL | 2025-10-03 | $3.4M | — | Filing → |